Macrogenics
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 339
- Market Cap
- $215.1M
- Introduction
MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E...
The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus
- First Posted Date
- 2006-10-11
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- MacroGenics
- Target Recruit Count
- 554
- Registration Number
- NCT00385697
- Locations
- 🇺🇸
Humphrey Diabetes Center, Boise, Idaho, United States
🇺🇸Research Institute of Dallas, Dallas, Texas, United States
🇺🇸Diabetes Medical Center of California, Northridge, California, United States
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
- First Posted Date
- 2005-01-19
- Last Posted Date
- 2022-02-22
- Lead Sponsor
- MacroGenics
- Target Recruit Count
- 53
- Registration Number
- NCT00101972
- Locations
- 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States
🇺🇸Premiere Oncology, Santa Monica, California, United States
🇺🇸Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States